Literature DB >> 31957702

IL-38 serum levels in patients with Behcet's disease and the relationship with clinical features.

Maryam Zarrabi1, Nasser Gholijani1, Saeedeh Shenavandeh2, Elham Aflaki2, Zahra Amirghofran3.   

Abstract

Behcet's disease (BD) is a chronic multisystem autoimmune disorder. Various cytokines take part in the pathogenesis of this disease. Interleukin (IL)-38, a new member of IL-1 cytokine family, has been reported to have anti-inflammatory properties; however, its role in BD has not been investigated yet. In this study, we aimed to examine the probable role of IL-38 in the clinical context of BD. A total of 81 patients with BD and 81 age- and sex-matched healthy subjects as controls were included in this study. The serum levels of IL-38 were measured in patients and controls sera using enzyme-linked immunosorbent assay. The relationship between the serum levels of IL-38 and clinical and laboratory characteristics of the patients were determined. IL-38 serum levels were significantly lower in patients in comparison with healthy controls at P = 0.003. We found significant differences between IL-38 levels in BD patients with positive and negative pathergy tests (P = 0.048) and patients with and without eye involvement (P = 0.046). Despite the absence of significant differences in serum levels between male and female patients, IL-38 levels were higher in female patients with a positive pathergy test (P = 0.048) and those patients with eye involvement (P = 0.046). As healthy controls showed higher IL-38 serum levels than patients, a protective anti-inflammatory role of IL-38 in BD is suggested. Together, these results suggest that the positive relationship between IL-38 serum levels and eye involvement that IL-38 may play a role in this clinical feature of the disease.

Entities:  

Keywords:  Behcet's disease; IL-38; autoimmune disease; cytokine

Mesh:

Substances:

Year:  2019        PMID: 31957702     DOI: 10.1684/ecn.2019.0430

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  5 in total

1.  Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients.

Authors:  Maryam Zarrabi; Mohammadali Nazarinia; Abbas Rahimi Jaberi; Nasser Gholijani; Zahra Amirghofran
Journal:  Med Princ Pract       Date:  2020-10-20       Impact factor: 1.927

2.  Low serum interleukin-38 levels in patients with Graves' disease and Hashimoto's thyroiditis.

Authors:  Jialu Xu; Guoqing Huang; Linjie Weng; Luping Gong; Yushan Mao; Yan Li; Mingcai Li
Journal:  J Clin Lab Anal       Date:  2021-11-19       Impact factor: 2.352

Review 3.  Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.

Authors:  Abdolreza Esmaeilzadeh; Nazila Bahmaie; Elham Nouri; Mohammad Javad Hajkazemi; Maryam Zareh Rafie
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

4.  Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019.

Authors:  Wasan W Al-Bassam; Ibtihal A Al-Karaawi; Inas K Sharquie; Ali H Ad'hiah
Journal:  J Med Virol       Date:  2022-04-14       Impact factor: 20.693

5.  Circulating interleukin-38 concentrations in healthy adults.

Authors:  Lisa U Teufel; Dennis M de Graaf; Mihai G Netea; Charles A Dinarello; Leo A B Joosten; Rob J W Arts
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.